Phosphate Suspension Chromium (III) radiolabelled with ³²P and ⁹⁰Y

Chronic synovitis is a manifestation common joint of rheumatoid arthritis, hemophilia and other systemic diseases. The modalities of treatment of this complication radiosynoviorthesis stands out for its good response, ease of implementation and lower total cost. In the United States, Europe and some countries in Latin America they are used to this different radioactive colloids and suspensions. In Cuba it was developed and is approved suspension Chromic Phosphate ³²P-labeled. At work the consistency of the production process of this suspension is examined. As a result of the evaluation was found that the suspension is characterized by a radiochemical purity of 94 ± 1% and particle size predominantly of 91 ± 3 between 0.2-10 microns. The results achieved in regular production and application to patients with rheumatic diseases and hemophiliacs, with follow-up to one year prove their efficacy and safety, the latter associated with low leakage articular detected and the absence of adverse reactions. Also at work the results achieved in the development of a technology for the production of suspension Phosphate Chromium (III) labeled with ⁹⁰Y, similarly to existing ³²P composition is exposed, and properties even more favorable, in particular radiochemical purity of 97%, favoring the registration of a radiopharmaceutical with better technical and economic characteristics, which must ensures the use of this form of treatment in the country. (author)